

# Kluwer Competition Law Blog

## International Law Talk Podcast: EU Competition Law Developments in the Pharmaceutical Sector with Michael Clancy and David Hull

Lena Hornkohl (Deputy Editor) (University of Vienna, Austria) · Thursday, June 3rd, 2021

We are happy to announce the new International Law Talk Podcast episode on EU competition law developments in the pharmaceutical sector. And this one is twice as good! Not only are we discussing both competition and IP issues, but I also interviewed two leading experts in the field: [Michael Clancy](#) and [David Hull](#) from [Van Bael & Bellis](#).

In the podcast, we touch upon new pharma developments regarding the Covid IP waivers, patent settlements, patent late life cycle strategies, biosimilars, excessive pricing, merger control and much more. [Listen to the podcast!](#)

In case you want to learn more on competition law and pharma, the new edition of the book by Van Bael & Bellis on [Competition Law of the European Union](#) has a great new section on the topic.

<https://competitionlawblog.kluwercompetitionlaw.com/wp-content/uploads/sites/51/2021/06/KLI-11-trailer.mp4>

---

*To make sure you do not miss out on regular updates from the Kluwer Competition Law Blog, please subscribe [here](#).*


## Kluwer Competition Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers are coping with increased volume & complexity of information. Kluwer Competition Law enables you to make more informed decisions, more quickly from every preferred location. Are you, as a competition lawyer, ready for the future?

Learn how **Kluwer Competition Law** can support you.

79% of the lawyers experience significant impact on their work as they are coping with increased volume & complexity of information.

**Discover how Kluwer Competition Law can help you.**  
Speed, Accuracy & Superior advice all in one.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change

This entry was posted on Thursday, June 3rd, 2021 at 10:00 am and is filed under [Dutch clause](#), [European Union](#), [Excessive pricing](#), [Intellectual property \(IP\)](#), [International Law Talk](#), [Merger control](#), [Patent settlements](#), [Pharmaceuticals](#), [Podcast](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. You can leave a response, or [trackback](#) from your own site.